2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1699 Clinical and molecular characterization of Mecom-rearranged myeloid neoplasms: A multicenter cohort study of 215 patients

Xinyue Zhang, Shaobin Yang, MD2, Yani Lin, PhD3, Kun Ru4
1 Sino-US Diagnostics Lab, Tianjin, China
2 Sino-US Diagnostics Lab, Tianjin, China
3 Sino-US Diagnostics Lab, Tianjin, China
4 Shandong Cancer Hospital and Institute, Shandong, China

Background:

MECOM (MDS1 and EVI1 complex locus) rearrangement defines a high-risk subset of myeloid neoplasms associated with poor outcomes and resistance to conventional therapy. However, comprehensive data on clinical features, mutational landscapes, and survival outcomes in large cohorts remain limited.

 

Aim:

To comprehensively characterize the clinical, cytogenetic, molecular features, and survival outcomes of MECOM-rearranged myeloid neoplasms in a large multicenter Chinese cohort, and to identify prognostic subgroups to inform risk stratification and therapeutic strategies.

 

Methods:

We retrospectively enrolled 215 patients with MECOM rearrangement detected by karyotyping and/or FISH from 39 institutions across China between November 2015 and July 2026. Clinical data, laboratory parameters, karyotypes, and treatment outcomes were collected. Targeted next-generation sequencing was performed in 74 patients. Survival endpoints included event-free survival (EFS), progression-free survival (PFS), and relapse-free survival (RFS). Statistical analyses were performed using Kaplan-Meier methods and log-rank tests.

 

Results:

The median age was 60 years (range, 15–84), with a balanced sex distribution (50.7% male). Diagnoses included AML (52.2%), MDS (27.3%), CML-BP (14.4%), and MPAL (2.8%). MECOM rearrangement was present at initial diagnosis in 176 patients (81.9%) and acquired during progression in 39 (18.1%). The progression-acquired group had significantly higher WBC counts (median 19.5 vs. 8.3 ×10?/L, p=0.01) and a higher proportion of CML-related cases (41.0% vs. 8.5%, p<0.001). Cytogenetically, inv(3)/t(3;3) was the most common rearrangement (122 cases, 56.7%), followed by t(3;21) (25, 11.6%), t(2;3) (20, 9.3%), t(3;12) (15, 7.0%), and t(3;7) (12, 5.6%). Complex karyotypes were present in 58 patients (27.0%). Common accompanying abnormalities included -7/del(7q) (n=71), +8 (n=18), and -5/5q- (n=12). Molecular profiling (n=74) revealed recurrent mutations in 91.9% of patients. The most frequently mutated genes were SF3B1 (31%), NRAS (26%), KRAS (24%), ASXL1 (19%), WT1 (14%), GATA2 (12%), TET2 (12%), PTPN11 (11%), RUNX1 (11%), and FLT3 (9%). RAS/MAPK pathway alterations (including NRAS, KRAS, PTPN11, NF1, and CBL) were observed in 47.3% of patients, and epigenetic modifiers (including ASXL1, TET2, DNMT3A, IDH1/2, and EZH2) were affected in 35.1%. Survival analysis showed a median EFS of 2.5 months (6-month rate 30.2%, 12-month rate 9.8%); median PFS was 7.5 months (6-month rate 61.5%, 12-month rate 38.5%); and median RFS was 7.5 months (6-month rate 66.7%, 12-month rate 53.3%). By karyotype, t(3;7) conferred the worst EFS (median 1.5 months), whereas t(2;3) was associated with more favorable outcomes (median PFS 10.0 months, event rate 60.0%). Complex karyotype was associated with inferior PFS (median 6.0 vs. 8.0 months; event rate 75.0% vs. 51.6%), and younger age (<60 years) predicted longer RFS (median 18.0 vs. 5.5 months).

 

Conclusions:

To our knowledge, this is the largest cohort study to date providing comprehensive characterization of MECOM-rearranged myeloid neoplasms. These patients exhibit a distinct molecular profile enriched for splicing factor mutations, RAS/MAPK pathway activation, and epigenetic alterations. Outcomes remain dismal, particularly in t(3;7) and t(3;3) subtypes, whereas t(2;3) appears relatively favorable. Complex karyotype and older age are adverse prognostic factors. These findings underscore the urgent need for novel therapeutic strategies in this high-risk population.

Xinyue Zhang: No relevant conflicts of interest to declare.